1,2-Dijod-benzocyclobutan | 6639-21-0

• 分子结构分类: 有机化合物 - 苯类化合物
• 英文名称: 1,2-Dijod-benzocyclobutan
• 英文别名: 7,8-Diiodobicyclo[4.2.0]octa-1,3,5-triene
• CAS: 6639-21-0
• 化学式: C₈H₆I₂
• 分子量: 355.945
• InChiKey: NDFPAKDLGIXZHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1,2-Dijod-benzocyclobutan 在 lithium aluminium tetrahydride 作用下， 生成 苯并环丁烯
  参考文献：
  名称：

  Zur darstellung o -Chinoider kohlenwasserstoffe und deren verhaltengegenüberphilodienen

  摘要：

  描述了形成中间邻双基的方法。这些极不稳定的碳氢化合物容易与其他活化组分发生加成反应。因此，发现可以应用Diels-Alder反应的加成原理，从而导致四氢化萘衍生物的形成。

  DOI：

  10.1016/s0040-4020(01)92168-4
• 作为产物：
  描述：

  四溴对烯 、 6-Methoxy-4a,5,8,8a-tetrahydronaphthalene-1,4-dione 、 碘化钠 、 N,N-二甲基甲酰胺 生成 1,2-Dijod-benzocyclobutan
  参考文献：
  名称：

  FARINA, F.;TORRES, T., AN. QUIM. PUBL. REAL SOC. ESP. QUIM., 1985, 81, N 2, 133-138

  摘要：

  DOI：

文献信息

• Enhancement of double-bond participation in the solvolysis of 9-isopropylidene-endo-3,4-benzotricyclo[4,2,1,02,5]non-3-en-7-yl toluene-p-sulphonates by the effect of nonbonded interactions
  作者：R. Baker、J. C. Salter

  DOI：10.1039/j29710000757

  日期：——

  The rates and products of acetolysis of 9-isopropylidene-endo-3,4-benzotricyclo-[4,2,1,02,5]non-3-en-7-yl toluene-p-sulphonates (4b) and (6b) have been determined and compared with the analogous derivatives in the norbornyl- and endo-3,4-benzotricyclo[4,2,1,02,5]non-3-ene systems. An explanation based on the effect of nonbonded interactions on the reaction co-ordinate for the ionisation of (6b), has

  9-异亚丙基-内-3,4-苯并三环-[4,2,1,0 2,5 ]非-3-en-7-基甲苯-对磺酸盐（4b）和（图6b）已经被确定并与在norbornyl-的类似衍生物比较，ENDO -3,4- benzotricyclo [4,2,1,0 2,5非3-烯体系。基于非键合相互作用对（6b）电离反应坐标的影响的解释已经提出，因为与可比的降冰片基相比，（6b）溶剂分解中发现的双键参与量更大导数（12）。根据（4b）溶剂分解的产物和速率研究，不能排除C（5）–C（6）键参与电离的微小贡献。
• DENDRITIC MOLECULAR INTRACELLULAR TRANSPORTERS AND METHODS OF MAKING AND USING SAME
  申请人：Harth Eva M.

  公开号：US20080221043A1

  公开（公告）日：2008-09-11

  In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to compounds comprising the structure: and at least one guanidinium residue, wherein m is zero or a positive integer. Also disclosed are methods of preparing the disclosed compounds. Also disclosed are methods of intracellular delivery comprising administering the disclosed compounds and compositions to a subject. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of one or more compounds or compositions of the invention and a pharmaceutically acceptable carrier. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  根据本发明的目的，本发明在一个方面涉及包含以下结构的化合物，以及至少一个鸟氨酸残基，其中m为零或正整数。还公开了制备所述化合物的方法。还公开了包括将所述化合物和组合物给予受试者的细胞内递送方法。还公开了包括本发明的一个或多个化合物或组合物的治疗有效量和药学可接受载体的制药组合物。本摘要旨在作为搜索特定领域的扫描工具，不限制本发明。
• MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES
  申请人：Harth Eva M.

  公开号：US20090306335A1

  公开（公告）日：2009-12-10

  In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymer and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明涉及聚合物、交联聚合物、功能化聚合物、纳米颗粒和功能化纳米颗粒以及其制备和使用方法。其中，本发明涉及可降解聚合物和可降解纳米颗粒。本发明还涉及制备可降解纳米颗粒的方法，更具体地说，涉及在制备可降解纳米颗粒过程中控制颗粒大小的方法。在一方面，这些可降解纳米颗粒可用于复合、传递和释放药物活性载荷等方面。本摘要旨在作为搜索特定技术领域的扫描工具，不限制本发明。
• Multifunctional Degradable Nanoparticles with Control over Size and Functionalities
  申请人：Harth Eva M.

  公开号：US20110257343A1

  公开（公告）日：2011-10-20

  In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymer and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  一方面，本发明涉及聚合物、交联聚合物、功能化聚合物、纳米颗粒和功能化纳米颗粒的制备和使用方法。另一方面，本发明涉及可降解聚合物和可降解纳米颗粒。另一方面，本发明涉及制备可降解纳米颗粒的方法，更具体地说，涉及在制备可降解纳米颗粒过程中控制颗粒大小的方法。另一方面，可降解纳米颗粒可用于复合、传递和释放药物活性载荷等用途。本摘要旨在作为搜索特定领域的扫描工具，不限制本发明。
• Dendritic Molecular Intracellular Transporters and Methods of Making and Using Same
  申请人：Vanderbilt University

  公开号：US20150315174A1

  公开（公告）日：2015-11-05

  In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to compounds comprising the structure: and at least one guanidinium residue, wherein m is zero or a positive integer. Also disclosed are methods of preparing the disclosed compounds. Also disclosed are methods of intracellular delivery comprising administering the disclosed compounds and compositions to a subject. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of one or more compounds or compositions of the invention and a pharmaceutically acceptable carrier. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  根据本发明的目的，本发明在一个方面涉及包含以下结构和至少一个鸟氨酸残基的化合物，其中m为零或正整数。还揭示了制备所述化合物的方法。还揭示了通过向受体注射所述化合物和组合物的方法进行细胞内递送。还揭示了含有本发明一种或多种化合物或组合物的治疗有效量和药学上可接受的载体的制药组合物。本摘要旨在用于搜索特定领域的扫描工具，不限制本发明。